Literature DB >> 9665135

The oncoprotein Evi-1 represses TGF-beta signalling by inhibiting Smad3.

M Kurokawa1, K Mitani, K Irie, T Matsuyama, T Takahashi, S Chiba, Y Yazaki, K Matsumoto, H Hirai.   

Abstract

Evi-1 encodes a zinc-finger protein that may be involved in leukaemic transformation of haematopoietic cells. Evi-1 has two zinc-finger domains, one with seven repeats of a zinc-finger motif and one with three repeats, and it has characteristics of a transcriptional regulator. Although Evi-1 is thought to be able to promote growth and to block differentiation in some cell types, its biological functions are poorly understood. Here we study the mechanisms that underlie oncogenesis induced by Evi-1 by investigating whether Evi-1 perturbs signalling through transforming growth factor-beta (TGF-beta), one of the most studied growth-regulatory factors, which inhibits proliferation of a wide range of cell types. We show that Evi-1 represses TGF-beta signalling and antagonizes the growth-inhibitory effects of TGF-beta. Two separate regions of Evi-1 are responsible for this repression; one of these regions is the first zinc-finger domain. Through this domain, Evi-1 interacts with Smad3, an intracellular mediator of TGF-beta signalling, thereby suppressing the transcriptional activity of Smad3. These results define a new function of Evi-1 as a repressor of signalling through TGF-beta.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9665135     DOI: 10.1038/27945

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  88 in total

Review 1.  Transcriptional control by the TGF-beta/Smad signaling system.

Authors:  J Massagué; D Wotton
Journal:  EMBO J       Date:  2000-04-17       Impact factor: 11.598

2.  A novel smad nuclear interacting protein, SNIP1, suppresses p300-dependent TGF-beta signal transduction.

Authors:  R H Kim; D Wang; M Tsang; J Martin; C Huff; M P de Caestecker; W T Parks; X Meng; R J Lechleider; T Wang; A B Roberts
Journal:  Genes Dev       Date:  2000-07-01       Impact factor: 11.361

3.  TGF-beta inhibits muscle differentiation through functional repression of myogenic transcription factors by Smad3.

Authors:  D Liu; B L Black; R Derynck
Journal:  Genes Dev       Date:  2001-11-15       Impact factor: 11.361

4.  BF-1 interferes with transforming growth factor beta signaling by associating with Smad partners.

Authors:  C Dou; J Lee; B Liu; F Liu; J Massague; S Xuan; E Lai
Journal:  Mol Cell Biol       Date:  2000-09       Impact factor: 4.272

5.  Overexpression of Evi-1 oncoprotein represses TGF-β signaling in colorectal cancer.

Authors:  Xiyun Deng; Yanna Cao; Yan Liu; Fazhi Li; Kamalanathan Sambandam; Srinivasan Rajaraman; Archibald S Perkins; Alan P Fields; Mark R Hellmich; Courtney M Townsend; E Aubrey Thompson; Tien C Ko
Journal:  Mol Carcinog       Date:  2011-12-07       Impact factor: 4.784

Review 6.  Evi-1 as a critical regulator of leukemic cells.

Authors:  Susumu Goyama; Mineo Kurokawa
Journal:  Int J Hematol       Date:  2010-06-08       Impact factor: 2.490

7.  Inactivation of menin, a Smad3-interacting protein, blocks transforming growth factor type beta signaling.

Authors:  H Kaji; L Canaff; J J Lebrun; D Goltzman; G N Hendy
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-13       Impact factor: 11.205

8.  Zinc finger protein 451 is a novel Smad corepressor in transforming growth factor-β signaling.

Authors:  Yili Feng; Hongxing Wu; Yongxian Xu; Zhengmao Zhang; Ting Liu; Xia Lin; Xin-Hua Feng
Journal:  J Biol Chem       Date:  2013-12-09       Impact factor: 5.157

Review 9.  Runx1/AML1 in normal and abnormal hematopoiesis.

Authors:  Tetsuya Yamagata; Kazuhiro Maki; Kinuko Mitani
Journal:  Int J Hematol       Date:  2005-07       Impact factor: 2.490

10.  Prdm16 is required for normal palatogenesis in mice.

Authors:  Bryan C Bjork; Annick Turbe-Doan; Mary Prysak; Bruce J Herron; David R Beier
Journal:  Hum Mol Genet       Date:  2009-12-11       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.